Ocaña L, Cos J, Quer J, Bilbao I, Palou E, Parra R, Sauleda S, Esteban J I, Guàrdia J, Massuet L I, Margarit C
Banc de Sang i Texits (BST), Barcelona, Spain.
Transplant Proc. 2005 Nov;37(9):3951-6. doi: 10.1016/j.transproceed.2005.09.183.
Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease and the reason for more than 50% of liver transplantations (OLT). Recurrent HCV infection occurs in almost all transplant recipients and has an unfavorable course. Although immunosuppressive agents are necessary to avoid allograft rejection, these drugs may favor viral replication facilitating viral-mediated graft injury.
To predict the evolution of two HCV(+) patients who underwent OLT, we studied INF-gamma and TNF-alpha production and the maturation capacity of dendritic cells (DCs) at three time points: before transplantation (Pre-Tx) and at 2 (2M) and 6 (6M) months after transplantation. Cytometric bead assays were used to quantify INF-gamma and TNF-alpha production in the supernates of mixed leukocyte reactions (MLR) between spleen cells from the liver donor and CD4(+) cells from the recipients. Immature and mature DCs were generated in vitro from patient monocytes.
The one patient who experienced recurrent HCV showed loss of CD4(+) responses to donor antigens and INF-gamma and TNF-alpha production after OLT. In contrast, the other patient maintained detectable levels of these cytokines after OLT. It was possible to generate mature DCs from monocytes with the aid of CD40L in both cases, but decreased expression of HLA-DR, CD80, and CD86 markers was observed upon posttransplantation analyses in the patient with recurrent HCV.
Loss of the proliferative response as well as INF-gamma and TNF-alpha production, together with a decreased HLA-DR, CD80, and CD86 (markers of mature DCs), indicated an inadequate immune response to viral progression in the liver transplant recipient with relapsing HCV infection.
丙型肝炎病毒(HCV)感染是慢性肝病的主要病因之一,也是超过50%肝移植(OLT)的原因。几乎所有移植受者都会发生复发性HCV感染,且病程不利。尽管免疫抑制剂对于避免同种异体移植排斥是必要的,但这些药物可能有利于病毒复制,促进病毒介导的移植物损伤。
为预测两名接受OLT的HCV(+)患者的病情发展,我们在三个时间点研究了干扰素-γ(INF-γ)和肿瘤坏死因子-α(TNF-α)的产生以及树突状细胞(DCs)的成熟能力:移植前(Pre-Tx)以及移植后2个月(2M)和6个月(6M)。采用细胞计数微珠分析法定量肝供体脾细胞与受体CD4(+)细胞之间混合淋巴细胞反应(MLR)上清液中INF-γ和TNF-α的产生量。从患者单核细胞体外培养出未成熟和成熟的DCs。
一名发生复发性HCV感染的患者在OLT后对供体抗原的CD4(+)反应以及INF-γ和TNF-α的产生均丧失。相比之下,另一名患者在OLT后这些细胞因子的水平仍可检测到。在两种情况下,借助CD40L均可从单核细胞生成成熟的DCs,但在复发性HCV感染患者移植后的分析中观察到HLA-DR、CD80和CD86标志物的表达降低。
增殖反应以及INF-γ和TNF-α产生的丧失,连同HLA-DR、CD80和CD86(成熟DCs的标志物)表达降低,表明复发性HCV感染的肝移植受者对病毒进展的免疫反应不足。